2. Search Result
Search Result
Results for "

CK2+Inhibitor

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50855
    Silmitasertib
    Maximum Cited Publications
    56 Publications Verification

    CX-4945

    		 Casein Kinase Autophagy Cancer
    Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib
  • HY-14394
    TBB
    10+ Cited Publications

    NSC 231634; Casein Kinase II Inhibitor I

    		 Casein Kinase Cancer
    TBB is a cell-permeable and ATP-competitive CK2 inhibitor with an IC50 of 0.15 μM for rat liver CK2.
    TBB
  • HY-50855B
    Silmitasertib sodium salt
    Maximum Cited Publications
    56 Publications Verification

    CX-4945 sodium salt

    		 Casein Kinase Autophagy Cancer
    Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib sodium salt
  • HY-15535
    DMAT
    5+ Cited Publications

    CK2 Inhibitor; Casein kinase II Inhibitor

    		 Casein Kinase Cancer
    DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.
    DMAT
  • HY-132175
    CK2 inhibitor 2

    		Casein Kinase Cancer
    CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .
    CK2 inhibitor 2
  • HY-108606
    PI-828
    2 Publications Verification

    		 PI3K Casein Kinase Cancer
    PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid kinase assay, respectively .
    PI-828
  • HY-115519
    (E/Z)-GO289
    2 Publications Verification

    		 Casein Kinase Cancer
    (E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC50=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function .
    (E/Z)-GO289
  • HY-15479
    TTP 22
    2 Publications Verification

    		 Casein Kinase Inflammation/Immunology Cancer
    TTP 22 is a potent CK2 inhibitor, with an IC50 of 100 nM and a Ki of 40 nM.
    TTP 22
  • HY-124833
    Quinalizarin

    		Casein Kinase Apoptosis Fungal Reactive Oxygen Species (ROS) Caspase MDM-2/p53 PARP Bcl-2 Family Akt ERK STAT JNK p38 MAPK CDK Infection Cancer
    Quinalizarin is a protein kinase CK2 inhibitor with a Ki of 0.052 μM. Quinalizarin exhibits antifungal and anticancer activities. Quinalizarin induces ROS production, apoptotic signaling, mitochondrial pathway activation, cell cycle arrest, and cytotoxicity in cancer cells. Quinalizarin inhibits hyphal growth, biofilm formation, and mature biofilm integrity of Candida albicans. Quinalizarin can be used in research related to cancer and fungal infections [2] .
    Quinalizarin
  • HY-50733A
    CX-5011

    		Casein Kinase Ras Apoptosis Cancer
    CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death [2].
    CX-5011
  • HY-B0183A
    Ellagic acid hydrate
    20+ Cited Publications

    		 Casein Kinase Cancer
    Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive CK2 inhibitor, with an IC50 of 40 nM and a Ki of 20 nM .
    Ellagic acid hydrate
  • HY-158369
    CK2-IN-10

    		Casein Kinase Cancer
    CK2-IN-10 (31), an allosteric CK2 inhibitor, can be used in the research of cancer .
    CK2-IN-10
  • HY-148328
    CK2-IN-4

    		Casein Kinase Infection Inflammation/Immunology Cancer
    CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC50=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis .
    CK2-IN-4
  • HY-50855R
    Silmitasertib (Standard)

    CX-4945 (Standard)

    		 Casein Kinase Autophagy Reference Standards Cancer
    Silmitasertib (Standard) is the analytical standard of Silmitasertib. This product is intended for research and analytical applications. Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib (Standard)
  • HY-50733
    CX-5011 free base

    		Apoptosis Casein Kinase Ras Cancer
    CX-5011 free base is a potent CK2 inhibitor. CX-5011 free base also is a Rac-1 activator. CX-5011 free base induces methuosis and promotes macropinocytosis. CX-5011 free base induces apoptosis. CX-5011 free base decreases the expression of rpS6 phosphorylation [2].
    CX-5011 free base
  • HY-123853
    CAM4066

    		Casein Kinase Cancer
    CAM4066 is a potent CK2α inhibitor, with an IC50 value of 300 nM. CAM4066 exhibits high selectivity, with IC50 values of 22.35, 43.55, and > 50 μM for HIPK3, DAPK3, and CLK2, respectively. CAM4066 shows no cell activity. CAM4066 can be used for the development of highly potent CK2 inhibitors .
    CAM4066
  • HY-169629
    CK2 inhibitor 4

    		Casein Kinase Cancer
    CK2 inhibitor 4 (compound 5b) is a protein kinase CK2 inhibitor with IC50 of 3.8 μM. CK2 inhibitor 4 can be used in tumor research .
    CK2 inhibitor 4
  • HY-143461
    CK2 inhibitor 3

    		Casein Kinase Cancer
    CK2 inhibitor 3 is a potent CK2 inhibitor with IC50 value of 280 nM. CK2 inhibitor 3 inhibits endocellular CK2, significantly affects viability of tumour cells and shows remarkable selectivity on a panel of 320 kinases .
    CK2 inhibitor 3
  • HY-174350
    CK2-IN-15

    		Casein Kinase SARS-CoV Infection
    CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .
    CK2-IN-15
  • HY-121792
    CK2-IN-1

    		Casein Kinase Others
    CK2-IN-1 is a CK2 inhibitor, with an IC50 of 150 nM .
    CK2-IN-1
  • HY-117332
    IQA

    CGP-029482

    		 Casein Kinase Cancer
    IQA (CGP-029482) is a potent and selective protein kinase CK2 inhibitor .
    IQA
  • HY-155987
    CK2-IN-8

    		Casein Kinase Cancer
    CK2-IN-8 (compound 5c) is a CK2 inhibitor with IC50 >33 μM .
    CK2-IN-8
  • HY-120267
    TID43

    		Casein Kinase Cardiovascular Disease
    TID43 is a CK2 inhibitor, with an IC50 of 0.3 μM. TID43 can be used for anti-angiogenic research .
    TID43
  • HY-148763
    CK2-IN-6

    		Casein Kinase Inflammation/Immunology Cancer
    CK2-IN-6 is a potent protein kinase CK2 inhibitor that can be used in the study of cancer as well as other kinase-related conditions, including inflammation, pain and certain immune diseases .
    CK2-IN-6
  • HY-50855BR
    Silmitasertib sodium salt (Standard)

    CX-4945 sodium salt (Standard)

    		 Casein Kinase Autophagy Reference Standards Cancer
    Silmitasertib (sodium salt) (Standard) is the analytical standard of Silmitasertib (sodium salt). This product is intended for research and analytical applications. Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib sodium salt (Standard)
  • HY-151382
    CK2-IN-3

    		Casein Kinase Cancer
    CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM), with IC50 values of 1.51 μM (CK2α) and 7.64 μM (CK2α’). CK2-IN-3 can be used in the research of cancers .
    CK2-IN-3
  • HY-158370
    CK2-IN-11

    		Casein Kinase Cancer
    CK2-IN-11 (32) is an allosteric CK2 inhibitor, with high selectivity for CK2 with IC50 values of 19.3 nM and 15.6 nM for the CK2α2β2 and the CK2α′2β2 isoforms, respectively .
    CK2-IN-11
  • HY-168517
    PIM-1/CK2-IN-2

    		Pim Casein Kinase Apoptosis Cancer
    PIM-1/CK2-IN-2 (compound 3aA) is a PIM-1/CK2 inhibitor. PIM-1/CK2-IN-2 can induce the mitochondrial apoptotic pathway in CCRF-CEM cells. PIM-1/CK2-IN-2 can be used in cancer research .
    PIM-1/CK2-IN-2
  • HY-183265
    GO847

    		Creatine Kinase ATP Synthase Mitochondrial Metabolism Reactive Oxygen Species (ROS) Cancer
    GO847 is an orally active casein kinase 2 (CK2) inhibitor with an IC50 of 40.2 nM. GO847 increases intracellular ATP levels, impairs Mitochondrial metabolic flexibility, and promotes excessive mitochondrial ROS production. GO847 alters the period length of cellular circadian rhythms. GO847 inhibits the growth of acute myeloid leukemia cells. GO847 can be used for the research of acute myeloid leukemia .
    GO847
  • HY-108606R
    PI-828 (Standard)

    		Reference Standards PI3K Casein Kinase Cancer
    PI-828 (Standard) is the analytical standard of PI-828 (HY-108606). This product is intended for research and analytical applications. PI-828 is a dual PI3K and casein Kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid Kinase assay, respectively .
    PI-828 (Standard)
  • HY-181022
    BMS-135

    		Casein Kinase Cancer
    BMS-135 is a potenr, selective and ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.8 and 0.3 nM for CK2αandCK2α′ isoforms. BMS-135 can simulate the structure of ATP and bind to the active pocket of CK2, thereby inhibiting its serine/threonine phosphorylation function. BMS-135 can inhibit cells proliferation and shows anti-tumor effect. BMS-135 can be used for research of colon cancer .
    BMS-135
  • HY-181442
    CK2-TN03

    		Casein Kinase Survivin Epigenetic Reader Domain Akt Apoptosis Caspase MDM-2/p53 Neurological Disease Cancer
    CK2-TN03 is an ATP-competitive casein kinase 2 (CK2) inhibitor, with an IC50 of 165 nM and a Ki of 20 nM. CK2-TN03 inhibits CK2-mediated survivin activation and reduces CK2-dependent phosphorylation levels of BRD4/MYCN and AKT1. CK2-TN03 exerts anti-neuroblastoma effects by inhibiting survivin, leading to mitotic catastrophe and apoptosis of cancer cells. CK2-TN03 can be used in studies related to neuroblastoma .
    CK2-TN03
  • HY-171744
    CX-5279

    		Casein Kinase Cancer
    CX-5279 is an efficient and selective CK2 inhibitor with IC50 values for nCK2 and CK2α of 2.73 and 0.91 nM, respectively. CX-5279 is sensitive to mutations at Val66, Ile174, and V66I174AA, with IC50 values of 13.8, 12.5, and 23.35 nM, respectively. CX-5279's inhibitory activity against PIM1 is very weak, with a IC50 value of 8.52 μM. CX-5279 exhibits anti-proliferative activity in various cancer cell lines. CX-5279 can be used for research on cancers such as pancreatic cancer and leukemia .
    CX-5279

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: